Toronto Memory Program is participating in TARBELA-AD, a Phase 2 clinical research study sponsored by Roche. The study is investigating an experimental oral medication called RO7568282, designed to target a process involved in inflammation in the brain. Researchers hope to better understand whether targeting this inflammatory process may help slow changes associated with Alzheimer’s disease. Participants will be randomly assigned to receive either the investigational medication or a placebo (an inactive treatment).
Who May Qualify?
If you are interested in participating, please complete the following preliminary qualification form.
We will follow-up with you after we have received your submission.